SuperworthXeris Biopharma shares outstanding XERS
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 172.8M
- On a year earlier
- +8.4%
- more shares
Xeris Biopharma had 172.8M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 8.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 178.3M | +20% |
| FY2024 | 149.2M | +8% |
| FY2023 | 138.1M | +2% |
| FY2022 | 136M | +12% |
| FY2021 | 121.5M | +127% |
| FY2020 | 53.5M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 172.8M | +8% | |
| Q1 FY26 | 177.6M | +17% | |
| Q4 FY25 | 178.3M | +20% | |
| Q3 FY25 | 177.6M | +19% | |
| Q2 FY25 | 159.5M | +7% | |
| Q1 FY25 | 152.4M | +8% | |
| Q4 FY24 | 149.2M | +8% | |
| Q3 FY24 | 149M | +8% | |
| Q2 FY24 | 148.3M | +8% | |
| Q1 FY24 | 140.5M | +2% | |
| Q4 FY23 | 138.1M | +2% | |
| Q3 FY23 | 138.1M | +2% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Xeris Biopharma
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.